Pancreatic Cancer Research

ResearcherTottori UniversityActive in the last 2 years

Teruhisa Sakamoto

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-8710-1511; OpenAlex author ID A5030519980. Sources: OpenAlex.

Their work

Papers
27 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
21
Papers, trials and grants by year

2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 2 papers · 2020: 3 papers · 2021: 5 papers · 2022: 2 papers · 2023: 3 papers · 2024: 3 papers · 2025: 1 paper · 2026: 5 papers

Papers 27

  1. Identification of TMEM115 as a tumor suppressor gene and clinical prognostic factor that influences TERT expression in pancreatic cancer. Co-author DOI 10.1038/s41598-026-49632-7↗
  2. The interactions between geriatric nutritional risk index and systemic immune-inflammation index for post-recurrence prognosis in patients with pancreatic canc… Co-author DOI 10.1186/s12957-026-04370-y↗
  3. Impact of CD73+CD39+ B Cells on Immune Evasion in Pancreatic Cancer. Co-author DOI 10.21873/anticanres.18437↗
  4. The Clinical Impact of Prognostic Nutritional Index at Recurrence of Pancreatic Cancer. Co-author DOI 10.21873/cdp.10573↗
  5. Clinical Impact of the C-Reactive Protein-Albumin-Lymphocyte Index as a Prognostic Biomarker in Patients With Recurrent Pancreatic Cancer. Co-author DOI 10.21873/invivo.14436↗
  6. Prognostic Relationship Between the Cachexia Index and Osteopenia in Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.17509↗
  7. The cachexia index is a prognostic factor for patients with recurrent pancreatic cancer. Co-author DOI 10.1007/s00595-024-02877-z↗
  8. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenoca… Co-author DOI 10.1016/j.hpb.2024.03.603↗
  9. Correlation between relative dose intensity of adjuvant S-1 chemotherapy and psoas muscle mass volume and survival after resection of pancreatic ductal adenoca… Co-author DOI 10.1097/md.0000000000038292↗
  10. TYRO3 promotes chemoresistance via increased LC3 expression in pancreatic cancer. Co-author DOI 10.1016/j.tranon.2022.101608↗
  11. High Glucose-stimulated aPKC Activation Promotes Pancreatic Cancer Cell Progression Through YAP Signaling. Co-author DOI 10.21873/anticanres.16681↗
  12. Current Value of Perioperative Therapies for Resectable or Borderline Resectable Pancreatic Cancer. First author DOI 10.33160/yam.2023.05.014↗
  13. Modified geriatric nutritional risk index in patients with pancreatic cancer: a propensity score-matched analysis. Co-author DOI 10.1186/s12885-022-10071-y↗
  14. Geriatric nutritional risk index as a prognostic factor in patients with recurrent pancreatic cancer. Co-author DOI 10.1371/journal.pone.0271073↗
  15. Human chromosome 3p21.3 carries TERT transcriptional regulators in pancreatic cancer. Co-author DOI 10.1038/s41598-021-94711-6↗
  16. The prognostic significance of combined geriatric nutritional risk index and psoas muscle volume in older patients with pancreatic cancer. Co-author DOI 10.1186/s12885-021-08094-y↗
  17. Decreased mean platelet volume predicts poor prognosis in patients with pancreatic cancer. Co-author DOI 10.1186/s12893-020-00976-5↗
  18. Cytoplasmic-only Expression of Maspin Predicts Unfavorable Prognosis in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.21873/anticanres.15032↗
  19. Anti-Tumor Effects of MAPK-Dependent Tumor-Selective Oncolytic Vaccinia Virus Armed with CD/UPRT against Pancreatic Ductal Adenocarcinoma in Mice. Co-author DOI 10.3390/cells10050985↗
  20. Oncogenic role of TYRO3 receptor tyrosine kinase in the progression of pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.11.028↗
  21. Sarcopenia as a prognostic factor in patients with recurrent pancreatic cancer: a retrospective study. Co-author DOI 10.1186/s12957-020-01981-x↗
  22. Prognostic Impact of Pre- and Post-operative P-CRP Levels in Pancreatic Cancer Patients. Co-author DOI 10.33160/yam.2020.02.011↗
  23. Combined preoperative platelet-to-lymphocyte ratio and serum carbohydrate antigen 19-9 level as a prognostic factor in patients with resected pancreatic cancer. Co-author DOI 10.1016/j.hbpd.2019.03.010↗
  24. Preoperative Albumin-Bilirubin Grade as a Useful Prognostic Indicator in Patients With Pancreatic Cancer. Co-author DOI 10.21873/anticanres.13260↗
  25. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Can… Co-author DOI 10.21873/anticanres.12883↗
  26. Prognostic indicators based on inflammatory and nutritional factors after pancreaticoduodenectomy for pancreatic cancer. Co-author DOI 10.1007/s00595-016-1308-6↗
  27. Nicotine enhances the malignant potential of human pancreatic cancer cells via activation of atypical protein kinase C. Co-author DOI 10.1016/j.bbagen.2016.07.008↗

Closest collaborators

The 21 strongest of 21 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yoshiyuki Fujiwara · 19 shared papers, 2018–2025 · strength 2.74
  2. Takehiko Hanaki · 17 shared papers, 2016–2024 · strength 2.38
  3. Masaki Morimoto · 13 shared papers, 2018–2026 · strength 2.08
  4. Mikiya Kishino · 8 shared papers, 2024–2026 · strength 1.88
  5. Takuki Yagyu · 8 shared papers, 2019–2026 · strength 1.17
  6. Yuki Murakami · 6 shared papers, 2021–2024 · strength 1.03
  7. Ei Uchinaka · 7 shared papers, 2018–2021 · strength 0.76
  8. Yoshihisa Umekita · 4 shared papers, 2020–2026 · strength 0.76
  9. Teppei Sunaguchi · 4 shared papers, 2022–2023 · strength 0.61
  10. Yoshiyuki Fujiwara · 2 shared papers, 2026 · strength 0.53
  11. Tatsuya Matsura · 4 shared papers, 2016–2023 · strength 0.50
  12. Yoshiyuki Fujiwara · 2 shared papers, 2024–2026 · strength 0.43
  13. Hiroyuki Kugoh · 2 shared papers, 2021–2026 · strength 0.40
  14. Masataka Amisaki · 5 shared papers, 2016–2019 · strength 0.39
  15. Joji Watanabe · 4 shared papers, 2016–2021 · strength 0.37
  16. Yu Sakano · 1 shared paper, 2026 · strength 0.28
  17. Yoshiyuki Fujiwara · 1 shared paper, 2026 · strength 0.26
  18. Kazushi Hara · 1 shared paper, 2023 · strength 0.17
  19. Hajime Kurosaki · 1 shared paper, 2021 · strength 0.14
  20. Takafumi Nakamura · 1 shared paper, 2021 · strength 0.14
  21. Masahide Ikeguchi · 2 shared papers, 2016 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.